Clinical Trial

ERG Components in Schizophrenia and Bipolar Disorder Type I

Study Description

ERG Components in Schizophrenia and Bipolar Disorder Type I

This study will further assess ERG components obtained with different ERG devices, to be considered in a prediction model for each diagnosis. The prediction models are diaMentis proprietary software used as an ERG-based diagnostic test (classified as a Software as Medical Device, SaMD) to support the diagnosis of schizophrenia and bipolar disorder type I. They involve the processing and analysis of specific retinal biosignatures (RSPA) with the support of statistical and mathematical modelling processes e.g. machine learning and statistical learning.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Device - ERG assessment (RSPA)

Processing and analysis of retinal signals

Additional Information

Official Study Title

Assessment of ERG Components to Discriminate Between Schizophrenia and Bipolar Disorder Type I

Clinical Trial ID

NCT03788811

ParticipAid ID

e73Owe